Previous 10 | Next 10 |
Merger activity decreased last week with two new deals announced and six pending deals closing. Deal Statistics: New Deals: The acquisition of Clementia Pharmaceuticals ( CMTA ) by Ipsen for $1.31 billion. Under the terms of the agreement, shareholders of Clementia Pharmaceutica...
MONTREAL, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the company will not report its fourth quarter and y...
Like a lot of players in the healthcare industry, it's a popular move to grow your offerings by acquiring other companies, and there have been thousands of such acquisition over the past few decades. Clementia Pharmaceuticals' ( CMTA ) primary drug development is called Palovarotene , which...
Gainers: China Internet Nationwide Financial Services (NASDAQ: CIFS ) +137% . Spark Therapeutics (NASDAQ: ONCE ) +120% . Clementia Pharmaceuticals (NASDAQ: CMTA ) +74% . uniQure N.V. (NASDAQ: QURE ) +30% . Titan Pharmaceuticals (NASDAQ: TTNP ) +27% . CRISPR Therapeutics AG (NASD...
Today's Top Stories: Monster rally in China after tariffs delayed; U.S.-British regulators move to ensure no Brexit disruption; and Barrick Gold proposes merger with Newmont Mining. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the follo...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). The Shanghai Composite surged 5.6% overnight, taking the index into bull market territory, after P...
Ipsen ( OTCPK:IPSEY ) has agreed to acquire Clementia Pharmaceuticals (NASDAQ: CMTA ) for $25 per share in cash plus a contingent value right (CVR) of $6 per share ($263M) related to the FDA acceptance of a marketing application seeking approval for lead drug palovarotene for the treatment...
Seeking to keep pace in gene therapy with rivals like Novartis (NYSE: NVS ), Roche ( OTCQX:RHHBY ) is buying Spark Therapeutics (NASDAQ: ONCE ) for $114.50 per share, or $4.3B, a premium of about 122% to Spark's closing price on Feb. 22. More news on: Novartis AG, Roche Holding Ltd ADR, ...
Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisition to transform Ipsen’s Rare Disease portfolio by leveraging C...
MONTREAL, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that management will host a conference call in conjunctio...
News, Short Squeeze, Breakout and More Instantly...
Clementia Pharmaceuticals Inc. Company Name:
CMTA Stock Symbol:
NASDAQ Market:
Clementia Pharmaceuticals Inc. Website:
TORONTO, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”),...
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement u...
MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business Corporations Act ...